Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinji Tamura

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Journal of Gastroenterology|May 22, 2013
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Journal of Gastroenterology|September 15, 2012
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelinesNaoki Harada, Naoki Hiramatsu, Tsugiko Oze, et al.
Journal of Medical Virology|March 19, 2016
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapyYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Journal of Hepatology|December 15, 2010
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2013
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2019
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic responseRyoko Yamada, Naoki Hiramatsu, Tsugiko Oze, et al.
Journal of Gastroenterology|November 24, 2011
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirinTsugiko Oze, Naoki Hiramatsu, Changho Song, et al.
Journal of Gastroenterology|May 10, 2011
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in JapanTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Journal of Gastroenterology|May 4, 2011
Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in JapanTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Gastroenterology|May 22, 2013
Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1Tsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Journal of Gastroenterology|September 15, 2012
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelinesNaoki Harada, Naoki Hiramatsu, Tsugiko Oze, et al.
Journal of Medical Virology|March 19, 2016
Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapyYuki Tahata, Naoki Hiramatsu, Tsugiko Oze, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2021
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus eliminationYuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Journal of Hepatology|December 15, 2010
Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2013
Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapyTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2019
Incidence and risk factors of hepatocellular carcinoma change over time in patients with hepatitis C virus infection who achieved sustained virologic responseRyoko Yamada, Naoki Hiramatsu, Tsugiko Oze, et al.
Journal of Gastroenterology|November 24, 2011
Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirinTsugiko Oze, Naoki Hiramatsu, Changho Song, et al.
Journal of Gastroenterology|May 10, 2011
The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in JapanTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Journal of Gastroenterology|May 4, 2011
Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in JapanTsugiko Oze, Naoki Hiramatsu, Takayuki Yakushijin, et al.
Pageof 10